PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 24, 2026Diabetes Obesity and Metabolism2 citationsOpen Access

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials

View Full Paper
MOMINNA B. OLSENJGJON GRIFFINUHUlrike Hövelmann

Key Points

  • This research aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of petrelintide for weight management.
  • Conducted two randomized, controlled Phase 1 trials.
  • Evaluated the incidence of gastrointestinal adverse events (TEAEs) and weight loss outcomes.
  • Analyzed pharmacokinetics and pharmacodynamics of petrelintide.
  • Petrelintide was found to be safe with a low incidence of gastrointestinal adverse events.
  • Participants experienced clinically relevant weight loss with the medication.
  • Findings suggest improved gastrointestinal tolerability compared to current therapies.

Abstract

Petrelintide appeared safe, had a low incidence of GI TEAEs, and resulted in clinically relevant weight loss. These findings support further development of petrelintide as an effective weight-management medication, with potential for improved GI tolerability over existing therapies.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

OLSEN et al. (2026) studied this question.

synapsesocial.com/papers/69eb0bc7553a5433e34b546chttps://doi.org/10.1111/dom.70753
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis2025 · 76 citations
  2. 2Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue2025 · 12 citations
  3. 3American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity2016 · 1,892 citations
  4. 4Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus2022 · 331 citations
  5. 5Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists2024 · 54 citations